Post-Transcriptional Regulators of Epidermal Homeostasis and Neoplasia

表皮稳态和肿瘤的转录后调节因子

基本信息

  • 批准号:
    10161730
  • 负责人:
  • 金额:
    $ 37.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-18 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Background: Transcriptional mechanisms that regulate epidermal homeostasis have been well established but recently we have discovered that post-transcriptional mechanisms play prominent roles in maintaining epidermal self-renewal. We have shown that the RNA helicase DDX6 is necessary to maintain epidermal self-renewal through the mRNA degradation and translation pathway. By associating with specific members of the translation pathway DDX6 binds to and mediates the translation of self- renewal and proliferation transcripts to maintain self-renewal. DDX6 also associates with mRNA degradation proteins to bind differentiation-inducing transcripts to promote their degradation to prevent premature differentiation. Objective/hypothesis: This proposal seeks to understand the regulation of epidermal homeostasis and tumor initiation through post-transcriptional mechanisms. We previously identified proteins associated with DDX6 and our objective is to characterize the role of each protein in regulating epidermal growth, differentiation, and progression to neoplasia as well as the mechanisms of action. Furthermore we seek to determine the specific transcripts that DDX6 and its associated complexes bind during homeostasis and tumor initiation. Specific Aims: (1) To determine the role of DDX6 associated proteins on epidermal homeostasis and tumor initiation and (2) to identify and characterize the transcripts associated with DDX6 complexes. Study Design: To study epidermal homeostasis in a more clinically relevant setting, we generate 3-dimensionally intact human skin, containing human epidermal cells (that have been permanently knocked down for either DDX6 or its associated proteins) in the context of human dermal stroma and basement membrane, regenerated on immune compromised mice. By using this model, we can perform loss of function experiments on DDX6 and its associated proteins in regenerated human skin to characterize their role in epidermal growth, differentiation, and progression to neoplasia. We will also use CLIP- Seq to determine the RNAs associated with DDX6 complexes during the progression from normal to neoplastic epidermis.
项目摘要/摘要 背景:调节表皮稳态的转录机制具有 已经建立得很好,但最近我们发现了转录后 机制在维持表皮自我更新方面起着重要作用。我们有 表明RNA解旋酶DDX6对于维持表皮自我更新是必要的 通过mRNA降解和翻译途径。通过与特定 翻译途径的成员DDX6与并介导的翻译 自我更新和增殖转录本以保持自我更新。 DDX6也是如此 与mRNA降解蛋白结合诱导分化的蛋白 成绩单以促进其降解以防止过早差异。 客观/假设:该提议旨在了解 通过转录后机制的表皮稳态和肿瘤起始。 我们以前以前确定了与DDX6相关的蛋白质,我们的目标是 表征每种蛋白质在调节表皮生长,分化, 和肿瘤的进展以及作用机理。此外,我们 寻求确定DDX6及其相关复合物的特定成绩单 在稳态和肿瘤开始期间结合。 具体目的:(1)确定DDX6相关蛋白在表皮上的作用 稳态和肿瘤的启动以及(2)识别和表征成绩单 与DDX6复合物相关。 研究设计:在更临床相关的环境中研究表皮稳态 我们产生3维完全完整的人皮肤,包含人表皮细胞 (已被永久击倒DDX6或其相关的 蛋白质)在人真皮基质和地下膜的背景下, 在免疫损害的小鼠上再生。通过使用此模型,我们可以执行 DDX6及其相关蛋白的功能实验损失在再生中 人体皮肤以表征其在表皮生长,分化和 发展为肿瘤。我们还将使用夹克确定RNA 从正常到肿瘤的进展过程中与DDX6复合物相关 表皮。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE L SEN其他文献

GEORGE L SEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE L SEN', 18)}}的其他基金

Regulation of Human Tumorigensis by Cancer Specific NXF1 Adaptor Proteins
癌症特异性 NXF1 接头蛋白对人类肿瘤发生的调节
  • 批准号:
    10411472
  • 财政年份:
    2022
  • 资助金额:
    $ 37.02万
  • 项目类别:
Regulation of epidermal growth and differentiation through mRNA export
通过 mRNA 输出调节表皮生长和分化
  • 批准号:
    10675700
  • 财政年份:
    2022
  • 资助金额:
    $ 37.02万
  • 项目类别:
Regulation of Human Tumorigensis by Cancer Specific NXF1 Adaptor Proteins
癌症特异性 NXF1 接头蛋白对人类肿瘤发生的调节
  • 批准号:
    10596156
  • 财政年份:
    2022
  • 资助金额:
    $ 37.02万
  • 项目类别:
Post-Transcriptional Regulators of Epidermal Homeostasis and Neoplasia
表皮稳态和肿瘤的转录后调节因子
  • 批准号:
    9916713
  • 财政年份:
    2018
  • 资助金额:
    $ 37.02万
  • 项目类别:
Regulation of Human Epidermal Tumorigenesis by the mRNA Degradation Pathway
mRNA 降解途径调控人表皮肿瘤发生
  • 批准号:
    10532171
  • 财政年份:
    2018
  • 资助金额:
    $ 37.02万
  • 项目类别:
Post-Transcriptional Regulators of Epidermal Homeostasis and Neoplasia
表皮稳态和肿瘤的转录后调节因子
  • 批准号:
    10402316
  • 财政年份:
    2018
  • 资助金额:
    $ 37.02万
  • 项目类别:
Regulation of Human Epidermal Tumorigenesis by the mRNA Degradation Pathway
mRNA 降解途径调控人表皮肿瘤发生
  • 批准号:
    10053717
  • 财政年份:
    2018
  • 资助金额:
    $ 37.02万
  • 项目类别:
Regulation of Human Epidermal Tumorigenesis by the mRNA Degradation Pathway
mRNA 降解途径调控人表皮肿瘤发生
  • 批准号:
    10304861
  • 财政年份:
    2018
  • 资助金额:
    $ 37.02万
  • 项目类别:
Limbal Stem Cell Fate and Corneal Specific Enhancers
角膜缘干细胞命运和角膜特异性增强剂
  • 批准号:
    9039606
  • 财政年份:
    2015
  • 资助金额:
    $ 37.02万
  • 项目类别:
Regulators of epidermal growth and differentiation
表皮生长和分化的调节剂
  • 批准号:
    10294731
  • 财政年份:
    2015
  • 资助金额:
    $ 37.02万
  • 项目类别:

相似海外基金

Role of miR-195 in Chemo-Resistant Ovarian Cancer
miR-195 在化疗耐药性卵巢癌中的作用
  • 批准号:
    10640540
  • 财政年份:
    2023
  • 资助金额:
    $ 37.02万
  • 项目类别:
Mechanisms of viral RNA maturation by co-opting cellular exonucleases
通过选择细胞核酸外切酶使病毒 RNA 成熟的机制
  • 批准号:
    10814079
  • 财政年份:
    2023
  • 资助金额:
    $ 37.02万
  • 项目类别:
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
R21 MPI microRNA 定向疗法治疗早期胰腺癌
  • 批准号:
    10577609
  • 财政年份:
    2023
  • 资助金额:
    $ 37.02万
  • 项目类别:
Engineering detours around the biologic barriers to allogeneic, iPSC-derived CAR T immunotherapy
工程绕开了同种异体、iPSC 衍生的 CAR T 免疫疗法的生物障碍
  • 批准号:
    10607952
  • 财政年份:
    2023
  • 资助金额:
    $ 37.02万
  • 项目类别:
CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease
CRISPR-Cas 编辑作为常染色体显性多囊肾病的基因治疗
  • 批准号:
    10822502
  • 财政年份:
    2023
  • 资助金额:
    $ 37.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了